ORIGINAL SCIENTIFIC REPORT



Effect of Glyceryl Trinitrate Ointment on Pain Control After Hemorrhoidectomy: A Meta-analysis of Randomized Controlled Trials

Jen-Wei ${\rm Liu}^1\cdot{\rm Chao-Chun}\;{\rm Lin}^2\cdot{\rm Kee-Thai}\;{\rm Kiu}^3\cdot{\rm Chun-Yu}\;{\rm Wang}^1\cdot{\rm Ka-Wai}\;{\rm Tam}^{2,4,5,6}$

Published online: 17 November 2015 © Société Internationale de Chirurgie 2015

Abstract

Background Hemorrhoidectomy is associated with postoperative pain and prolonged wound healing. Glyceryl trinitrate has been shown to decrease muscle spasm and increase anodermal blood flow. A meta-analysis of randomized controlled trials was conducted to evaluate the efficacy of topical glyceryl trinitrate application in pain relief after hemorrhoidectomy.

Methods PubMed, EMBASE, Cochrane Library, Scopus, and ClinicalTrials.gov registries were searched for studies published before August 2015. Individual effect sizes were standardized, and a meta-analysis was conducted to calculate a pooled effect size using random effects models. Pain was assessed using a visual analog scale on days 1, 3, 7, and 14 after operation. Secondary outcomes included time taken to resume routine activities, wound healing at 3 weeks after operation, complication, and headache incidence.

Results A total of 12 trials with 1095 patients were reviewed. Significant pain reduction was observed on days 1, 3, 7, and 14 after hemorrhoidectomy in the glyceryl trinitrate groups. Glyceryl trinitrate-treated patients appeared to resume routine activities earlier than those in the control group (weight mean difference -7.52; 95 % confidence interval: 16.13–1.08). The wound healing rates 3 weeks after operation were significant higher in the glyceryl trinitrate-treated groups than in the control group (risk ratio 1.79; 95 % confidence interval: 1.38–2.33). However, the incidence of headache significantly increased in the glyceryl trinitrate group (risk ratio 3.68; 95 % confidence interval: 1.62–8.34).

Conclusion Topical application of glyceryl trinitrate effectively relieves pain and promotes wound healing after hemorrhoidectomy; however, the substantial headache incidence may limit extensive application.

Ka-Wai Tam kelvintam@h.tmu.edu.tw

- ¹ Department of Pharmacy, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
- ² Center for Evidence-based Health Care, Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan
- ³ Division of Colorectal Surgery, Department of Surgery, Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan
- ⁴ Division of General Surgery, Department of Surgery, Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan
- ⁵ Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- ⁶ Center for Evidence-based Medicine, College of Medicine, Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan

Introduction

Hemorrhoidectomy is the most effective and the safest treatment for high-grade hemorrhoids. However, hemorrhoidectomy is associated with postoperative pain and prolonged wound healing, which may delay patients' resumption of routine activities [1]. Hemorrhoidectomy is treated through several surgical procedures, such as the Milligan–Morgan (open) hemorrhoidectomy or Ferguson techniques. In addition, stapled hemorrhoidectomy for prolapse and hemorrhoids reduces postoperative pain and enables early resumption of routine activities; however, these procedures are associated with a higher recurrence rate [2].

The cause of postoperative pain is multifactorial, spasm of anal sphincter, and puborectalis muscles have been implicated as one of various potential mechanisms [3]. Pain severity depends on various factors, including individual pain tolerance, anesthesia type, surgical technique, postoperative analgesia, and stool softener use [4]. Traditionally, postoperative pain has been reduced using narcotics or nonsteroid anti-inflammatory drugs; however, their use is confined to a short period and is associated with frequent side effects [5].

Glyceryl trinitrate (GTN), a nitric oxide donor, has been shown to decrease muscle spasm and increase anodermal blood flow [6, 7]. Topical application of GTN is commonly used to relieve pain and promote wound healing in patients with anal fissure [8, 9]. Two randomized controlled trials (RCTs) have investigated the topical use of GTN after hemorrhoidectomy; however, these studies could not provide conclusive results [10, 11]. A recent meta-analysis suggested that GTN ointment had a significant analgesic effect at days 3 and 7 after hemorrhoidectomy and significantly improved wound healing within 3 weeks [12]. However, this review did not clarify the heterogeneity of the pooled results, which is crucial in the random effects model [13]. Moreover, several RCTs evaluating GTN in pain control after hemorrhoidectomy have been published recently [14, 15]. Therefore, through a systematic review and meta-analysis of the evidence available to date, we investigated the outcome in patients using GTN topically after hemorrhoidectomy.

Materials and methods

Inclusion criteria

RCTs evaluating the outcome of topical application of GTN in open, closed, or stapled hemorrhoidectomy were included in this review. Studies were also required to clearly report the inclusion and exclusion criteria for patients, the anesthetic technique, the surgical technique, and the definition and evaluation of postoperative pain. We excluded trials that met at least one of the following criteria: (1) patients undergoing other surgical procedures concomitantly, such as transanal hemorrhoidal dearterialization; (2) patients had previously undergone nonhemorrhoid surgery, such as anal sphincterotomy or dilatation for anal fissure; or (3) patient cohorts reported in duplicates.

Search strategy and study selection

Relevant studies published before August 2015 were identified from the PubMed, Embase, Scopus, and Cochrane databases. The following Medical Subject Headings terms were used: hemorrhoid, hemorrhoidectomy, glyceryl trinitrate OR nitroglycerin OR GTN, analgesia OR pain. The "related articles" option in PubMed was used to broaden the search, and all abstracts, studies, and citations retrieved were reviewed. In addition, we identified other studies using the reference sections of relevant papers and by corresponding with subject experts. Finally, unpublished studies were collected from the ClinicalTrials.gov registry (http://clinicaltrials.gov/). No language restrictions were applied. The systematic review described herein has been accepted by PROSPERO, an online international prospective register of systematic reviews, curated by the National Institute for Health Research (CRD42015023274).

Data extraction

Baseline and outcome data were independently abstracted by 2 reviewers (JWL and KWT), and the study designs, study population characteristics, inclusion and exclusion criteria, surgical and anesthetic techniques, drug administration strategies, complications, and postoperative parameters were extracted. Decisions recorded individually by the reviewers were compared, and disagreements were resolved by the third reviewer (KTK). The authors of the studies were contacted for additional information.

Methodological quality appraisal

Two reviewers (JWL and KWT) independently assessed the methodological quality of each study using the risk of bias method recommended by the Cochrane Collaboration [16]. Several domains were assessed, including adequacy of the randomization, allocation concealment, blinding of the patients and outcome assessors, length of follow-up, information provided to the participants regarding study withdrawals, whether intention-to-treat analysis was performed, and freedom from other biases.

Outcomes

The primary outcome was the occurrence and severity of postoperative pain, which was measured on days 1, 3, 7, and 14 after the operation. The secondary outcomes included analgesia consumption, complication, incidence of head-aches, wound healing rate, and work resumption date.

Statistical analyses

Data were entered and analyzed using the Review Manager, version 5.3 (The Cochrane Collaboration, Oxford, England). Meta-analysis was performed in line with the PRISMA guidelines [17]. Standard deviations were estimated from the provided confidence interval limits or standard error. Dichotomous outcomes were analyzed using risk ratios (RRs) as the summary statistic. Effect sizes of continuous outcomes were reported as the weighted mean difference (WMD). The precision of the effect sizes were reported as 95 % confidence intervals (CIs). A pooled estimate of the RR and WMD was computed using the DerSimonian and Laird random effect model [18].

To evaluate statistical heterogeneity and inconsistency of treatment effects across studies, Cochrane Q tests and I^2 statistics, respectively, were used. Statistical significance was set to p < 0.10 for Cochrane Q tests. Statistical heterogeneity across studies was assessed using the I^2 test, which quantified the proportion of the total outcome variability across the studies. Moreover, subgroups analyses were performed by pooling available estimates for similar subsets of patients across trials.

Results

Trial characteristics

Figure 1 is a flowchart describing the screening and selection of trials. The initial search strategy yielded 496 citations, and 348 among these were ineligible based on the criteria used for screening titles and abstracts. Thus, the full texts of 148 studies were retrieved. However, most were excluded from our final review because of the following reasons: 8 were retrospective studies or prospective articles; 118 included treatment for other diseases, such as anal fissure surgery; 5 evaluated the effects of local anesthesia using different interventions, such as botulinium toxin; and 5 discussed other topics concerned with hemorrhoid surgery. Thus, 12 studies were eligible for inclusion in this study [10, 11, 14, 15, 19–26] (Table 1).

These 12 trials were published between 2001 and 2014 and had sample sizes ranging from 20 to 210 patients.




Table 1 Characteristics of the selected randomized controlled trials

Study	Inclusion criteria	Setting	No. of patients (% male)	Age, years	Intervention		
Cross [14]	Third- and fourth- degree	GA; stapled hemorrhoidectomy	G: 100 (57) C: 110 (67)	G: 49.8 (22–79) ^a C: 50.6 (22–79)	G: 0.2 % GTN ointment 3 times daily × 2 weeks		
hemorrhoids					C: control		
Di Vita [10]	Third- and fourth- degree hemorrhoids	GA; 1 surgeon; Milligan–Morgan hemorrhoidectomy	G: 15 (60) P: 15 (53)	G: 35 ± 20 P: 40.6 ± 18	G: Lactulose 20 ml × 2 days before + 2 weeks after surgery; metronadizole IV 400 mg before + 400 mg tid × 7 days after surgery; 0.2 % GTN ointment 3 times daily × 2 weeks		
					P: placebo		
Elton [11]	Third- degree hemorrhoids	GA; 2 surgeons; Milligan–Morgan	G: 10 (80) P: 10 (40)	G: 53.9 P: 52.6	G: 0.2 % GTN ointment twice daily × 42 days		
		hemorrhoidectomy			P: placebo ointment twice daily \times 42 days		
Franceschilli [15]	Third- and fourth- degree	LA; Milligan– Morgan	G: 103 (58.3) C: 100 (65)	G: 45.6 ± 10 C: 51.5 ± 12	G: 0.4 % GTN ointment twice daily × 42 days		
	hemorrhoids	hemorrhoidectomy with Ligasure			C: control		
Hwang [19]	Third- and fourth-	SA; 1 surgeon;	G: 55 (76.4)	G: 41.8 ± 12.1	G: 0.2 % GTN ointment 3 times a day \times 3		
	degree hemorrhoids	Milligan–Morgan hemorrhoidectomy	P: 55 (71.1)	P: 41.7 ± 10.1	weeks P: placebo		
Karanlik [20]	Third- and fourth- degree	GA; Ferguson hemorrhoidectomy	G: 30 (50) P: 30 (53)	G: 34.4 ± 10.8 P: 36.6 ± 10.4	G: 0.2 % GTN ointment twice daily × 2 weeks		
	hemorrhoids	-	1.50 (55)	1. 50.0 ± 10.4	P: placebo		
Khan [26]	Third- and fourth-	GA or SA; Milligan-	G: 70	G: 41.7 ± 9.3	G: 0.2 % GTN ointment twice daily		
	degree	Morgan	L: 70	L: 43.4 ± 8.5	L: 2 % lidocaine ointment twice daily		
	hemorrhoids	hemorrhoidectomy	G + L: 70	G + L: 41.2 ± 10.1	G + L: 0.2 % GTN + 2 % lidocaine ointment twice daily		
Mari [21]	Second- and third- degree	GA or SA; stapled hemorrhoidectomy	G: 21 (71) L: 20 (65)	G: 48.7 ± 9.0 L: 48.3 ± 8.6	G: 0.4 % GTN ointment twice daily × 2 weeks		
	hemorrhoids		L. 20 (03)	D. 40.5 ± 0.0	L: 2.5 % lidocaine chlorohydrate gel twice daily × 2 weeks		
Patti [22]	Third- and fourth- degree	GA; Milligan– Morgan	G: 30 (30)	G: 33 ± 15	G: 0.2 % GTN ointment 3 times daily × 15 days		
	hemorrhoids	hemorrhoidectomy	P: 30 (26)	P: 36 ± 18	P: placebo		
Patti [23]	Third- and fourth-	GA; 1 surgeon;	G: 15 (46)	G: 38 ± 16	G: 0.2 % GTN ointment 3 times daily \times 30		
1 atti [20]	degree	Milligan–Morgan	B: 15 (53)	$B: 40 \pm 15$	days		
	hemorrhoids	hemorrhoidectomy			B: 0.4 ml of 20 IU botulinum toxin		
Tan [24]	Third- and fourth-	GA; open diathermy	G: 40 (72.5)	G: 45.8 ± 11.6	G: 0.2 % GTN ointment 3 times daily \times 2		
	degree hemorrhoids	hemorrhoidectomy	P: 42 (76.2)	P: 39.9 ± 9.6	weeks P: placebo		
Wasvary	Patients for	SA; Ferguson	G: 19 (42.1)	G: 54	G: 0.2 % GTN ointment 3 times daily \times 7		
[25]	hemorrhoidectomy	hemorrhoidectomy	P: 20 (60)	P: 49	days P: placebo		

B botulinum group, C control group, G glyceryl trinitrate group, GA general anesthesia, GTN glyceryl trinitrate, L lidocaine group, LA local anesthesia, NTG nitroglycerin, P placebo group, SA spinal anesthesia

^a Data are presented as mean \pm SD except mean (range)

Nine trials recruited patients with third- and fourth-degree hemorrhoid [10, 14, 15, 19, 20, 22–26]. Milligan–Morgan hemorrhoidectomy was performed in the majority of the included trials; Ferguson-closed hemorrhoidectomy was

performed in 2 studies [20, 25], and stapled hemorrhoidectomy was performed in 2 trials [14, 21]. Nine trials compared the effects of GTN topical application and a control or placebo [10, 11, 14, 15, 19, 20, 22, 24, 25].

 Table 2
 Assessment of methodological quality of included studies

Study [year]	Country	Allocation generation	Allocation concealment	Blinding of patients and assessors	Data analysis	Loss to follow- up (%)	Selective reporting	Other bias
Cross [14]	Australia	Computer generated	Unclear	Assessor blinded	ITT	2.9	Low risk	Lack of clinical supervision in application of GTN ointment
Di Vita [10]	Italy	Unclear	Unclear	iclear Unclear		0	Complication not evaluated	-
Elton [11]	London	Random numbers	Adequate	Double blinded	ITT	0	Low risk	Male is predominant in GTN group
Franceschilli [15]	Italy	Shuffling method	Adequate	Unclear	ITT	0	Low risk	-
Hwang [19]	Korea	Computer generated	Adequate	Double blinded	PP	7.3	Low risk	_
Karanlik [20]	Turkey	Computer generated	Unclear	Double blinded	РР	13	Low risk	-
Khan [26]	Pakinstan	Computer generated	Unclear	Double blinded	РР	8.6	Low risk	Duration of experimental drugs used was not provided
Mari [21]	Italy	Computer generated	Unclear	Patient blinded	ITT	0	Low risk	-
Patti [22]	Italy	Unclear	Unclear	Unclear	ITT	0	Low risk	-
Patti [23]	Italy	Computer generated	Unclear	Assessor blinded	ITT	0	Low risk	-
Tan [24]	Singapore	Sealed envelopes	Adequate	Double blinded	PP	17.2	Low risk	-
Wasvary [25]	Michigan	Unclear	Adequate	Double blinded	ITT	0	Low risk	-

Risk of bias was assessed according to the method recommended by the Cochrane collaboration

ITT intention-to-treat, PP per-protocol

GTN outcomes combined with the use of lactulose and metronidazole were investigated in one of these 9 trials [10]. Two studies evaluated the results between topical application of GTN and lidocaine chlorohydrate gel [21, 26], and one trial assessed the anesthetic effects of botulinum toxin [23]. GTN and placebo dosages were adjusted according to various protocols. Baseline characteristics in the treatment groups of the 12 included RCTs were balanced.

The methodological quality of the included trials is summarized in Table 2. Nine studies reported acceptable methods of randomization [11, 14, 15, 19–21, 23, 24, 26]. Three studies did not describe the blinding of patients and outcome assessors [10, 15, 22]. Eight studies used intention-to-treat analysis [10, 11, 14, 15, 21–23, 25]. The number of patients lost to follow-up was acceptable (<20 %) in all studies. Biases in the selected studies included a lack of clinical supervision in the application of GTN ointment [14]; males were predominant in the GTN groups [11]; and no mention on the duration of experimental drugs used [26].

Pain score

Postoperative pain had been assessed in 10 studies through a 10-point visual analog scale (0 = no pain, 10 = severepain) [10, 14, 15, 19–25], whereas two studies used a 0–100 scale [11, 26]. The 12 studies were converted to a 10-point scale to compare the outcome measures. These measured outcomes on days 1, 3, 7, and 14 after the operation were compared because of variation in pain assessment time among the studies. Data obtained from 7 RCTs were included; data from 5 were excluded because the studies reported only median and range [14] or mean visual analog scores without standard deviation [11, 23, 25, 26]. The pooled mean difference in degree of pain score were -1.24(95 % CI -2.42 to -0.06) on day 1, -1.77 (-2.82 to -0.06)-0.71) on day 3, -2.21 (-3.08 to -1.33) on day 7, and -1.15 (-1.72 to -0.59) on day 14 after operation. The GTN group showed significantly reduced postoperative pain when compared with the control group (Fig. 2). The value of I^2 was 0–96 % at different time points after the operation, indicating low to severe heterogeneity across the

		GTN		Co	ontro	I		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
2.1.1 Pain scores at o	day 1								
Di Vita 2004	3.8	7	15	4.8	5.8	15	5.1%	-1.00 [-5.60, 3.60]	
Hwang 2003	2.9	0.6	49	4.2	1	53	21.3%	-1.30 [-1.62, -0.98]	•
Karanlik 2009	5.4	1.3	30	8.8	0.7	30	20.7%	-3.40 [-3.93, -2.87]	•
Mari 2013	3.6	1	21	3.6	1.2	20	20.2%	0.00 [-0.68, 0.68]	+
Patti 2005	4.4	1.9	30	5.5	1.5	30	19.3%	-1.10 [-1.97, -0.23]	-=-
Tan 2006	5	5	40	5	4	42	13.5%	0.00 [-1.97, 1.97]	
Subtotal (95% CI)			185			190	100.0%	-1.24 [-2.42, -0.06]	-
Heterogeneity: Tau ² =	1.68; Cł	ni² = 7	′3.03, c	lf = 5 (P	< 0.0)0001);	I² = 93%		
Test for overall effect:	Z = 2.06	5 (P =	0.04)						
2.1.2 Pain scores at o	day 3								
Franceschilli 2013	2	1	103	4.3	1	100	18.0%	-2.30 [-2.58, -2.02]	
Hwang 2003	2.8	1.2	49	3	0.6	53	17.8%	-0.20 [-0.57, 0.17]	+
Karanlik 2009	4.2	1.5	30	7	1	30	17.1%	-2.80 [-3.45, -2.15]	-
Mari 2013	2.5	1	21	4	1.1	20	17.1%	-1.50 [-2.14, -0.86]	
Patti 2005	3.6	1.3	30	7	1.1	30	17.2%	-3.40 [-4.01, -2.79]	-
Tan 2006	4	3.9	40	4	3.5	42	12.8%	0.00 [-1.61, 1.61]	
Subtotal (95% CI)			273			275	100.0%	-1.77 [-2.82, -0.71]	◆
Heterogeneity: $Tau^2 =$ Test for overall effect:	Z = 3.29		,	```	Ρ<υ	.00001); I² = 96%)	
2.1.3 Pain scores at o	-	10	45	4	07	15	11 00/		
Di Vita 2004		1.9 1.8	15		2.7 1.4	15	11.6%	-2.50 [-4.17, -0.83]	-
Franceschilli 2013 Karanlik 2009	4.1	1.0 1	103 30		1.4	100 30	19.3% 18.4%	-3.40 [-3.84, -2.96]	-
Mari 2013	1.9	1	21		1.4	20	18.4%	-3.40 [-4.02, -2.78] -1.40 [-2.04, -0.76]	
Patti 2005		0.7	30		0.6	30	19.7%	-1.90 [-2.23, -1.57]	-
Tan 2006	3	4	40		2.9	42	12.6%	0.00 [-1.52, 1.52]	_ _
Subtotal (95% CI)	5	4	239	5	2.5	237		-2.21 [-3.08, -1.33]	◆
Heterogeneity: Tau ² =	0.97: Cł	1i² = <i>!</i>		lf = 5 (P	< 0 (
Test for overall effect:					0.0	,,	51,0		
2.1.4 Pain scores at o	day 14								
Mari 2013	0.4	0.7	21	1.6	1.3	20	76.9%	-1.20 [-1.84, -0.56]	
Tan 2006	1	2.9	40	2	2.5	42	23.1%	-1.00 [-2.17, 0.17]	
Subtotal (95% CI)			61			62	100.0%	-1.15 [-1.72, -0.59]	◆
Heterogeneity: Tau ² = Test for overall effect:	'		,	`	= 0.77	7); l² = (0%		
									⊢ − − + − +
									-10 -5 0 5 Favours GTN Favours co

Fig. 2 Forest plot of comparison: GTN ointment application versus control; outcome: incidence of postoperative pain on days 1, 3, 7, and 14

studies (Fig. 2). Subgroup analysis according to surgical types was performed. In patients who had undergone Milligan–Morgan, Ferguson, or stapled hemorrhoidectomy, our analysis revealed that GTN application in the treated groups significantly reduced pain compared with the control group.

The studies excluded from the meta-analysis reported varied results. Patti et al. compared with the effect of topical application of GTN and the injection of botulinum toxin on pain relief after hemorrhoidectomy and reported that a single intrasphincter injection of botulinum toxin was more effective than repeated applications of GTN in reducing early postoperative pain during rest but not during defecation [23]. Khan et al. reported that statistically significant reductions in pain scores from day 1 to 4 after operation in GTN and lidocaine combination group [26]. Three studies also revealed less pain in the GTN group but with nonsignificant differences compared with the control group [11, 14, 25].

Analgesic consumption

Analgesic consumption was reported in 10 trials [10, 11, 19–26]. Data pooling for analgesia consumption could not be performed because the clinical parameters among the selected trials were not uniformly reported. No significant difference was reported in the requirements for postoperative analgesia between the study groups in 5 of the selected trials [10, 11, 19, 22, 24]. Khan et al. reported that no significant difference in the use of analgesics between lidocaine and GTN groups [26]. However, Karanlik et al. and Wasvary et al. have shown that patients in the GTN group consumed significantly lower amounts of analgesics than those in the placebo group [20, 25]. Mari et al. reported that all 20 patients took analgesics in the lidocaine gel group, whereas only 5 patients took analgesics in the GTN group (p < 0.0001) [21].

Time to resume routine activity

The time necessary to resume routine activities was reported in 3 trials [15, 20, 22]. Although the difference is nonsignificant, GTN-treated patients appeared to resume routine activities earlier than the untreated patients did (WMD -7.52; 95 % CI -16.13 to 1.08) (Fig. 3). Moreover, Di Vita et al. reported that the time for patients in the GTN group to resume routine activities was significantly earlier than for those in the control group (p < 0.05) [10].

Wound healing rate

Wound healing 3 weeks after operation was reported in 3 trials [19, 20, 24]. Patients treated with GTN exhibited significantly more wound healing compared with the control group (RR 1.79; 95 % CI 1.38–2.33) (Fig. 4). Moreover, Patti et al. reported that the GTN group showed significantly faster epithelial healing rate than did the control group (22.7 ± 4.3 vs. 32.1 ± 7.2 days, p < 0.05) [22]; and Khan et al. indicated that patients in the GTN group had a mean healing time of 4.48 weeks as compared to 5.07 weeks for lidocaine group [26].

Complications

Among the included studies, no significant differences was observed in the GTN and control groups' bleeding-

	(GTN		C	ontrol			Mean Difference		N	lean Differer	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV,	Random, 95	5% CI	
Franceschilli 2013	13	6	103	27.2	15.8	100	32.7%	-14.20 [-17.51, -10.89]			•		
Karanlik 2009	10.3	1.8	30	10.7	1.4	30	34.2%	-0.40 [-1.22, 0.42]			•		
Patti 2005	16.5	3.8	30	24.8	7.1	30	33.1%	-8.30 [-11.18, -5.42]			-		
Total (95% CI)			163			160	100.0%	-7.52 [-16.13, 1.08]			•		
Heterogeneity: Tau ² =	56.10; C	Chi² =	84.80,	df = 2 (P < 0.0	00001);	l² = 98%						
Test for overall effect:	Z = 1.71	(P =	0.09)						-100	-50 Favour	0 s GTN Favo	50 ours control	100

Fig. 3 Forest plot of comparison: GTN ointment application versus control; outcome: time to resume normal activities

	GTN	1	Contr	ol		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Rand	om, 95% (CI	
Hwang 2003	35	49	21	53	49.1%	1.80 [1.24, 2.63]					
Karanlik 2009	23	30	14	30	37.5%	1.64 [1.07, 2.53]					
Tan 2006	17	40	8	42	13.4%	2.23 [1.09, 4.58]					
Total (95% CI)		119		125	100.0%	1.79 [1.38, 2.33]			•		
Total events	75		43								
Heterogeneity: Tau ² =	0.00; Chi ²	= 0.54	, df = 2 (F	9 = 0.76	i); l² = 0%					+	
Test for overall effect:	Z = 4.33 (P < 0.0	001)				0.01 0. Favo	1 urs control	Favours (10 GTN	100

Fig. 4 Forest plot of comparison: GTN ointment application versus control; outcome: wound healing rate within 3 weeks after operation

associated postoperative complications [14, 15, 19, 20, 24], urinary retention [14, 19, 20, 22, 24], fecal impaction [14, 24], itching [15, 19, 20, 24], and residual skin tags [19, 24] (RR 0.92; 95 % CI 0.63–1.34) (Fig. 5).

Headache incidence

All studies provided data on headache incidence. An analysis revealed that 10.5 % (50/478) of the patients in the GTN group experienced headaches. GTN application in the treated groups was significantly associated with more headache compared with the control, (RR 3.68; 95 % CI 1.62–8.34) (Fig. 6).

Discussion

Postoperative pain and difficulties in defecation are major clinical problems following hemorrhoidectomy. This metaanalysis indicated that topical GTN application following hemorrhoid surgery shows a significant pain reduction on days 1, 3, 7, and 14 after operation. GTN-treated patients had faster wound healing rate 3 weeks after operation and were able to resume routine activities earlier compared with the control group. However, application of GTN was associated with an increased headache incidence.

GTN topical application for acute and chronic fissure treatment has been evaluated for approximately 20 years

	GTN	1	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Corss 2012	17	100	19	110	39.8%	0.98 [0.54, 1.79]	
Elton 2001	1	10	1	10	2.0%	1.00 [0.07, 13.87]	
Hwang 2003	10	49	15	53	28.8%	0.72 [0.36, 1.45]	
Karanlik 2009	3	30	6	30	8.5%	0.50 [0.14, 1.82]	
Patti 2005	1	30	1	30	1.9%	1.00 [0.07, 15.26]	
Tan 2006	10	40	7	42	18.9%	1.50 [0.63, 3.56]	
Total (95% CI)		259		275	100.0%	0.92 [0.63, 1.34]	•
Total events	42		49				
Heterogeneity: Tau ² =	0.00; Chi ²	= 2.61	, df = 5 (F	e = 0.76	5); l ² = 0%		
Test for overall effect:	Z = 0.43 (I	P = 0.6	7)				0.01 0.1 1 10 Favours GTN Favours cont

Fig. 5 Forest plot of comparison: GTN ointment application versus control; outcome: incidence of postoperative complications

	GTN	I	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI
Corss 2012	5	100	2	110	16.6%	2.75 [0.55, 13.86]	
Di Vita 2004	0	15	0	15		Not estimable	
Elton 2001	2	10	2	10	14.9%	1.00 [0.17, 5.77]	
Franceschilli 2013	13	103	0	100	7.2%	26.22 [1.58, 435.25]	
Hwang 2003	1	49	3	53	10.5%	0.36 [0.04, 3.35]	
Karanlik 2009	2	30	0	30	6.4%	5.00 [0.25, 99.95]	
Khan 2014	7	61	0	64	7.1%	15.73 [0.92, 269.56]	
Mari 2013	6	21	0	20	7.2%	12.41 [0.74, 206.86]	
Patti 2005	4	30	1	30	11.2%	4.00 [0.47, 33.73]	
Tan 2006	2	40	0	42	6.4%	5.24 [0.26, 105.97]	
Wasvary 2001	8	19	1	20	12.5%	8.42 [1.16, 61.10]	
Total (95% CI)		478		494	100.0%	3.68 [1.62, 8.34]	•
Total events	50		9				
Heterogeneity: Tau ² =	0.37; Chi²	= 11.40	6, df = 9 (P = 0.2	5); l² = 21	%	
Test for overall effect:	Z = 3.12 (F	⊃ = 0.00	02)				0.002 0.1 1 10 50 Favours GTN Favours control

Fig. 6 Forest plot of comparison: GTN ointment application versus control; outcome: incidence of headache

[27–29]. Systematic reviews have indicated that medical therapy may cure chronic and acute anal fissures and fissures in children. Medical therapies for adults with chronic fissures are less effective than surgery is [30, 31]. However, a previous meta-analysis investigating the role of GTN after hemorrhoidectomy has reported that GTN has a significant analgesic effect and improves wound healing within 3 weeks [12]. In an updated review, 8 more RCTs were included in the analysis [10, 11, 14, 15, 21, 23, 26], and the analgesic efficacy of GTN in the early (day 1) and late (day 14) postoperative period was validated. Moreover, the current study reports that GTN application was significantly associated with more headaches, but this relationship was statistically nonsignificant in the previous meta-analysis [12].

The optimal topical GTN dosage is inconclusive. In the included trials, a high GTN dose (0.4 % twice daily) [15, 21] revealed lesser analgesic effects than did a low dose (0.2 % 2 or 3 times daily). No difference of GTN toxicity, such as postoperative complications, was observed, and headache incidences were reported in both low and high doses of experimental drugs.

Previous studies have shown that a third of the patients do not comply because of GTN-induced headache [12]. Our study revealed a 10.5 % incidence of headache in GTN-treated patients. In one of the included studies, Tan et al. documented a case of severe headaches requiring treatment cessation of simple analgesics [24]. The application of GTN was discontinued in 3.27–17 % of patients because of local discomfort and headaches in 3 trials [14, 15, 26]. Mari et al. reported 6 patients with headaches in the GTN group; 4 of them reduced the GTN dose by 50 % and reported cessation of headaches [21]. However, most included trials reported that headaches were not clinically significant to discontinue GTN ointment use in clinical practice and can be controlled using simple analgesics such as paracetamol.

Other RCTs had evaluated the effects of topical diltiazem or nifedipine, a calcium channel blocker, in reducing pain after hemorrhoidectomy [32–34]. These studies noticed no significant difference in morbidity between intervention and control groups. Therefore, diltiazem or nifedipine seems to be an effective alternative ointment of GTN to prevent headaches. However, the efficacy of these drugs in reducing pain and analgesic tablets consumption are still questionable [32, 34]. Further research focusing on these outcomes is warranted.

The studies included in our analysis displayed considerable heterogeneity because of various clinical factors. First, surgical techniques were not the same across all studies and included open, closed, and stapled hemorrhoidectomy. Second, some trials did not standardize the preoperative protocol [10]. Finally, the experimental drug dosage application differed across studies. Such diversities among studies resulted in heterogeneity.

The study has several limitations. First, some trials had a small sample size of 10 patients recruited per treatment group. Second, only 3 studies reported the measurements of postoperative anal pressure changes [21–23], a measure of reduced postoperative pain, and enhanced healing. Finally, several of the primary and secondary outcomes were variably reported; the wound healing was judged by a clinician and is therefore subjective, thereby potentially limiting the inference of our analysis.

In conclusion, our meta-analysis revealed that GTN application after hemorrhoidectomy significantly decreases pain and reduces the wound healing time compared with a placebo. However, an approximately 10 % headache incidence was found in the GTN group. Therefore, if patients want pain relief and early wound healing time, they may opt for GTN application after hemorrhoidectomy, and the resulting headaches can be dealt with simple analgesics.

Funding support This work was supported by a research grant from Taipei Medical University and Shin Kong Wu Ho-Su Memorial Hospital (Grant no. SKH-TMU-103-07). The sponsoring organization was not involved in the study design, data analysis, or interpretation.

Disclosure The authors Jen-Wei Liu, Chao-Chun Lin, Kee-Thai Kiu, Chun-Yu Wang, and Ka-Wai Tam have no conflicts of interest or financial ties to disclose.

References

- MacRae HM, McLeod RS (1995) Comparison of hemorrhoidal treatment modalities: a meta-analysis. Dis Colon Rectum 38: 687–694
- Burch J, Epstein D, Sari AB et al (2009) Stapled haemorrhoidopexy for the treatment of haemorrhoids: a systematic review. Colorectal Dis 11:233–243; discussion 243
- Cheetham MJ, Mortensen NJ, Nystrom PO, Kamm MA, Phillips RK (2000) Persistent pain and faecal urgency after stapled haemorrhoidectomy. Lancet 356:730–733
- Ganio E, Altomare DF, Gabrielli F, Milito G, Canuti S (2001) Prospective randomized multicentre trial comparing stapled with open haemorrhoidectomy. Br J Surg 88:669–674
- Goldstein ET, Williamson PR, Larach SW (1993) Subcutaneous morphine pump for postoperative hemorrhoidectomy pain management. Dis Colon Rectum 36:439–446
- Schouten WR, Briel JW, Auwerda JJ, Boerma MO (1996) Anal fissure: new concepts in pathogenesis and treatment. Scand J Gastroenterol Suppl 218:78–81
- Kua KB, Kocher HM, Kelkar A, Patel AG (2001) Effect of topical glyceryl trinitrate on anodermal blood flow in patients with chronic anal fissures. ANZ J Surg 71:548–550
- Poh A, Tan KY, Seow-Choen F (2010) Innovations in chronic anal fissure treatment: a systematic review. World J Gastrointest Surg 2:231–241
- Utzig MJ, Kroesen AJ, Buhr HJ (2003) Concepts in pathogenesis and treatment of chronic anal fissure—a review of the literature. Am J Gastroenterol 98:968–974

- Di Vita G, Patti R, Arcara M, Petrone R, Davì V, Leo P (2004) A painless treatment for patients undergoing Milligan-Morgan haemorrhoidectomy. Ann Ital Chir 75:471–474
- Elton C, Sen P, Montgomery AC (2001) Initial study to assess the effects of topical glyceryl trinitrate for pain after haemorrhoidectomy. Int J Surg Investig 2:353–357
- Ratnasingham K, Uzzaman M, Andreani SM, Light D, Patel B (2010) Meta-analysis of the use of glyceryl trinitrate ointment after haemorrhoidectomy as an analgesic and in promoting wound healing. Int J Surg 8:606–611
- Siddiqui MR, Daulatzai N (2011) Re: meta-analysis of the use of glyceryl trinitrate ointment after haemorrhoidectomy as an analgesic and in promoting wound healing. Int J Surg 9:272
- 14. Cross T, Bartlett L, Mushaya C, Ashour M, Ho YH (2012) Glyceryl trinitrate ointment did not reduce pain after stapled hemorrhoidectomy: a randomized controlled trial. Int Surg 97:112–119
- Franceschilli L, D'Ugo S, de Luca E et al (2013) Role of 0.4% glyceryl trinitrate ointment after haemorrhoidectomy: results of a prospective randomised study. Int J Colorectal Dis 28:365–369
- Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org
- 17. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34
- DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
- Hwang DY, Yoon SG, Kim HS, Lee JK, Kim KY (2003) Effect of 0.2 percent glyceryl trinitrate ointment on wound healing after ahemorrhoidectomy: results of a randomized, prospective, double-blind, placebo-controlled trial. Dis Colon Rectum 46:950–954
- Karanlik H, Akturk R, Camlica H, Asoglu O (2009) The effect of glyceryl trinitrate ointment on posthemorrhoidectomy pain and wound healing: results of a randomized, double-blind, placebocontrolled study. Dis Colon Rectum 52:280–285
- 21. Mari FS, Nigri G, Dall'Oglio A et al (2013) Topical glyceryl trinitrate ointment for pain related to anal hypertonia after stapled hemorrhoidopexy: a randomized controlled trial. Dis Colon Rectum 56:768–773
- 22. Patti R, Arcara M, Padronaggio D et al (2005) Efficacy of topical use of 0.2% glyceryl trinitrate in reducing post-haemorrhoidectomy pain and improving wound healing. Chir Ital 57:77–85
- 23. Patti R, Almasio PL, Arcara M et al (2006) Botulinum toxin vs. topical glyceryl trinitrate ointment for pain control in patients

undergoing hemorrhoidectomy: a randomized trial. Dis Colon Rectum 49:1741-1748

- 24. Tan KY, Sng KK, Tay KH, Lai JH, Eu KW (2006) Randomized clinical trial of 0.2 per cent glyceryl trinitrate ointment for wound healing and pain reduction after open diathermy haemorrhoidectomy. Br J Surg 93:1464–1468
- 25. Wasvary HJ, Hain J, Mosed-Vogel M, Bendick P, Barkel DC, Klein SN (2001) Randomized, prospective, double-blind, placebo-controlled trial of effect of nitroglycerin ointment on pain after hemorrhoidectomy. Dis Colon Rectum 44:1069–1073
- 26. Khan K, Waqas A, Akmal M, Mahmood S, Iqbal A (2014) Efficacy of combination of 0.2% GTN and lignocaine ointments in wound healing and pain relief after Milligan Morgan hemorrhoidectomy—a comparison with lignocaine and 0.2% GTN ointments separately. Int J Surg 12:329–333
- Lund JN, Scholefield JH (1997) A randomised, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure. Lancet 349:11–14
- Kennedy ML, Sowter S, Nguyen H, Lubowski DZ (1999) Glyceryl trinitrate ointment for the treatment of chronic anal fissure: results of a placebo-controlled trial and long-term followup. Dis Colon Rectum 42:1000–1006
- Altomare DF, Rinaldi M, Milito G et al (2000) Glyceryl trinitrate for chronic anal fissure-healing or headache? Results of a multicenter, randomized, placebo-controled, double-blind trial. Dis Colon Rectum 43:174–179; discussion 179–181
- Nelson R (2004) A systematic review of medical therapy for anal fissure. Dis Colon Rectum 47:422–431
- Nelson RL, Thomas K, Morgan J, Jones A (2012) Non surgical therapy for anal fissure. Cochrane Database Syst Rev 15(2):CD003431
- 32. Perrotti P, Dominici P, Grossi E, Cerutti R, Antropoli C (2010) Topical nifedipine with lidocaine ointment versus active control for pain after hemorrhoidectomy: results of a multicentre, prospective, randomized, double-blind study. Can J Surg 53:17–24
- 33. Silverman R, Bendick PJ, Wasvary HJ (2005) A randomized, prospective, double-blind, placebo-controlled trial of the effect of a calcium channel blocker ointment on pain after hemorrhoidectomy. Dis Colon Rectum 48:1913–1916
- 34. Sugimoto T, Tsunoda A, Kano N, Kashiwagura Y, Hirose K, Sasaki T (2013) A randomized, prospective, double-blind, placebo-controlled trial of the effect of diltiazem gel on pain after hemorrhoidectomy. World J Surg 37:2454–2457. doi:10.1007/ s00268-013-2124-